Running Title: amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Moreover, we demonstrate that CADY is not toxic and enters cells through a mechanism which is independent of the major endosomal pathway. Given its biological properties, we propose that CADY-based technology will have significant impact on the development of fundamental and therapeutic siRNA-based applications.
INTRODUCTION
Over the past ten years, we have witnessed the emergence of numerous therapeutic approaches based on nucleic acids or analogues affecting expression of target genes [1] . The discovery of RNA interference has raised great hope for many therapies by providing a means to interfere with specific gene products [2, 3] . Several reports have revealed that siRNA (small interfering RNA) can be applied to inhibit targets implicated in various diseases including cancer, viral infections and genetic disorders [4] [5] [6] [7] .
The field of derivate therapeutic applications is in continuous development, however, the major limitation to the clinical application of these methods is the poor permeability of cell membrane to negatively charged nucleic acids and their restricted bio-distribution [5] [6] [7] .
In order to circumvent these issues, research has focused on the development of efficient delivery strategies and have lead to the design of different viral vectors [4] [5] [6] [7] and non-viral approaches for siRNA delivery, including electroporation [8] , cationic lipids and polymers [9] , nanoparticles [10] and peptides [11, 12] . Cell Penetrating Peptides (CPPs) have been shown to significantly improve cellular uptake of various therapeutic molecules both in cultured cells and in vivo [13, 14] . Most of the CPPs that have been proposed so far, such as siRNA in a fully biologically active form into a wide variety of cell lines, including embryonic stem cells [24, [30] [31] [32] [33] .
Amongst the new CPP-based delivery systems proposed that enable siRNA to cross cell membranes, only a few possess the properties of a therapeutic carrier including high delivery efficiency, absence of cytotoxicity and of immunogenicity. Efficient uptake allows decreasing the dose required to achieve a significant effect, thereby decreasing secondary side effects associated with a lack of specificity. In the present work, we propose a new generation of CPPs, based on a secondary amphipathic peptide CADY, which is able to form stable complexes with siRNA and improves their delivery into challenging suspension and primary cell lines. We demonstrate that CADY promotes target knockdown with sub-nanomolar concentrations of siRNA, without inducing any toxic side effects. We have investigated the mechanism through which CADY mediates cellular uptake of siRNA and show that CADY possesses great potential as a carrier for siRNA-mediated targeting in a therapeutic context.
RESULTS

Design and characterization of CADY.
Delivery of siRNA into suspension cells remains a major challenge for therapeutic applications. Therefore in order to favour cellular uptake of siRNA into challenging cell lines, we designed a new generation of peptide carriers that adopt a helical structure with secondary amphipathic properties. We have previously reported that the chimeric peptide carrier PPTG1 derived from the fusion peptide JTS1 [34] , in which all glutamic acids are replaced by lysines or arginines, forms stable complexes with nucleic acids and improves their delivery both in cultured cells and in vivo [35] . Based on PPTG1 sequence as a template, we designed a 20-residue secondary amphipathic peptide, CADY, "Ac-GLWRALWRLLRSLWRLLWRAhal-00345886, version 1 -5 Feb 2009 spectroscopy, using the four Trp-residues of CADY as internal probes to monitor the interaction with siRNA. The binding of siRNA to CADY induced 42% quenching of fluorescence, associated with a 7 nm blue-shift of the emission spectrum from 345 nm to 338 nm ( Fig. 2b and insert) . CADY presents high affinity for siRNA and fitting of the titration curve yields an apparent dissociation constant of 15.2 ± 2 nM. Binding saturation was reached at a molar ratio ranging between 5/1 and 10/1, suggesting that several molecules of CADY interact with the siRNA molecule, in agreement with agarose gel results. Interestingly, no shift in the emission spectrum associated with an increase in diffusion was observed with higher molar ratios (40/1) (Fig. 2b insert) , suggesting that high molecular weight complexes reported in agarose gel assays are not aggregates but bona fide complexes. We have investigated the impact of the interaction of CADY with siRNA on its stability to serum nuclease. The siRNA were complexed with increasing CADY molar ratios and then incubated for 24 h in the presence of 50% serum (Fig. 2c) . In the absence of CADY or in the presence of low molar ratios (1/1 to 10/1), siRNAs are rapidly degraded by serum. In contrast, no significant degradation was observed at high molar ratios (40/1 and 80/1) and the stability of siRNA to serum within CADY particles increased with the ratio of CADY, indicating that CADY protects the siRNA. That siRNAs retain their integrity when complexed to CADY is consistent with the high affinity of CADY for siRNA and the formation of a particle of peptides surrounding the siRNA.
CADY promotes efficient cellular uptake of siRNA into mammalian cells
We next evaluated the potency of CADY to deliver siRNA into cultured cells using fluorescently labelled siRNA molecules (FAM-siRNA). A fixed concentration of siRNA (20 nM) was complexed with CADY at different molar ratios ranging from 10/1 to 80/1 and internalization was monitored by FACS. CADY-mediated cellular uptake of siRNA is hal-00345886, version 1 -5 Feb 2009 extremely rapid and similar results were obtained for short (30 min) or long (4h) incubation times. As reported in Fig. 3 , cellular uptake efficiency was directly related to the molar ratio of CADY/siRNA. Although a 10/1 ratio was sufficient to deliver siRNA into almost every cell, the intracellular fluorescence intensity increased with the CADY/siRNA ratio and doubled between 10/1 and 80/1 ratios. The fluorescence peaks observed at ratios 10/1 and 20/1 are symmetric, revealing a homogeneous cellular distribution of siRNA. In contrast, at a greater ratio (80/1) the increase in fluorescence intensity is associated with a broader peak; mainly due to heterogeneity in the size of siRNA/CADY complexes and the consequent heterogeneous cellular incorporation of FAM-siRNA, in perfect correlation with results obtained by fluorescence spectroscopy and gel-shift assay.
CADY-mediated siRNA delivery into mammalian cells induces target knockdown.
The potency of CADY to deliver active siRNA molecules into cells was investigated by monitoring knockdown of GAPDH, at both mRNA and protein levels (Fig. 4) . U 2 OS cells were incubated with different siRNA concentrations ranging from 0.5 to 20 nM complexed with CADY at a molar ratio of 40/1 or 80/1. CADY/siRNA complexes were formed at a siRNA concentration of 20 nM, then in order to obtain a homogeneous solution of CADY/siRNA complexes, lower concentrations of siRNA were prepared by serial dilution in 0.5 x PBS. GAPDH mRNA level was quantified 24 h after transfection using the quantitative Quantigene assay (Fig. 4a) and knockdown of GAPDH protein levels was evaluated 48 hours after transfection by Western blot analysis (Fig. 4b&c) (Fig. 4 b&c) . Taken together, these experiments show a direct correlation between mRNA and protein knockdown and reveal that the biological effect of CADY-delivered siRNA is dependent on the carrier/cargo ratio and on the siRNA concentration.
To determine whether there was a link between siRNA uptake (20 nM) and side effects, the cytotoxicity of CADY was evaluated on U 2 OS cells with different CADY/siRNA ratios using the MTT assay. As reported in 3T3C cell lines. CADY/siRNA complexes formed at a molar ratio of 40/1 were used and the siRNA dose-response associated GAPDH knockdown was followed at both protein and mRNA levels. As reported in Fig. 5 , CADY-mediated siRNA delivery induced an important knockdown of GAPDH at both the mRNA and protein level in all cell lines tested.
Remarkably, the mRNA level was reduced by more than 80% with 20 nM siRNA, irrespective of the cell type, and IC 50 values of about 3.4 ± 0.5 nM, 1.5 ± 0.1 nM and 1.2 ± 0.1 nM were estimated for THP1 (Fig. 5a ), primary HUVEC ( Fig. 5b) and 3T3C (Fig. 5c) cells.
Monitoring the level of cyclophilin B mRNA as control of cell viability, showed no significant toxicity associated with siRNA/CADY, and viability was greater than 80% in all cell lines (Fig. 5) .
Cell entry mechanism of CADY/siRNA complexes
In order to better understand the cellular uptake mechanism of CADY/siRNA particles, the CADY-mediated cell-entry of a fluorescently-labelled siRNA was investigated in the presence of different inhibitors of the endocytosis pathway. Cells were treated with amiloride, known to inhibit cell entry associated with macropinocytosis [20, 21] , nocodazole for the clathrin-mediated pathway [37] and cyclodextrin for caveolin-and microdomain-associated processes [20] . The cellular uptake of fluorescently-labelled siRNA was determined by flow cytometry and correlated with GAPDH siRNA associated biological response. Results were normalized with a control experiment performed in the absence of inhibitors. As reported in different inhibitors also revealed a concentration-dependent increase in the efficiency associated with amiloride treatment up to 16 % for a concentration of 2.5 mM (Fig. 6b) correlating with the improvement in cellular uptake of the fluorescently-labelled siRNA..
When cells were treated with nocodazole, a 22% increase in GAPDH knockdown efficiency was observed. In contrast cholesterol depletion by methylcyclodextrin (5 mM) resulted in a weak (7 %) inhibition of transfection efficiency.
DISCUSSION
It is currently admitted that siRNA molecules hold amazing therapeutic potential for the development of new drugs interfering with various diseases [5, 7, 9, 38] . However, siRNAbased therapies, as most nucleic acid-based strategies, have to face limitations associated with poor cellular uptake and bio-distribution. Therefore, although several non-viral methods have been reported to improve siRNA delivery [5] [6] [7] optimizing stability and cellular uptake of siRNA molecules into primary cell lines remains a major challenge. In the present study, we report the design and characterization of a new amphipathic peptide carrier, CADY, which promotes siRNA delivery into challenging cell lines. We have demonstrated that CADY meets four major requirements (i) binds reversibly and forms stable complexes with short nucleic acids, (ii) crosses the cell membrane of a broad spectrum of cell types, including primary, suspension and adherent cell lines, (iii) selectively and rapidly delivers siRNA into the cytoplasm and (iv) promotes a significant siRNA-associated knockdown of the target.
CADY is a secondary amphipathic peptide derived from PPTG1 peptide which has been reported to improve delivery of plasmid DNA into both cultured cells and in vivo, but not of small nucleic acids [35] . The sequence of PPTG1 was optimized in order to specifically interact with small nucleic acids (siRNA) and to improve the stability of the peptide/small nucleic acid interactions, in particular, by replacing with Trp and Arg, seven residues hal-00345886, version 1 -5 Feb 2009 throughout the sequence of PPTG1. Arginines have been shown to both improve electrostatic cell surface interactions and to enhance cellular entry of CPPs [16, 40] . Tryptophan plays an essential role in the cellular uptake of CPPs [18, 27, 41, 42] mainly due to their ability to interact with lipid/cholesterol molecules within the membrane. Moreover, in the case of noncovalent peptide-based strategies, Trp-residues are involved in stabilization of carrier/cargo complexes [27, 42] . Secondary amphipathic peptides are generated by the conformational state which allows positioning of hydrophobic and hydrophilic residues on opposite sides of the molecule. CADY adopts a helical conformation in solution and molecular modelling reveals that the lowest energy structural model corresponds to an amphipathic helical conformation stabilized by the stacking and exposure of Trp-residues on one side, of Arg and Lys-charged residues on the other and of hydrophobic residues on yet another (Fig. 1d) . The spatial conformation of CADY improves its solubility and its interaction with siRNA.
The high affinity of CADY for siRNA (Kd :15.2 nM) is essentially associated with electrostatic interactions involving Arg residues, but most likely also implies Trp residues that may interact with the minor groove of siRNA molecules. It was recently shown that Trp of the p19 protein that controls siRNA silencing in plants interacts with and makes an endcapping interaction with the 5'end of siRNA [43] . The combination of electrostatic interactions and of hydrogen bonding leads to the formation of stable CADY/siRNA particles which protect siRNA molecules without affecting their silencing activity. The stability of these complexes was validated by the fact that no serum nuclease degradation and a long term silencing response was observed, with 60% knockdown of the target gene after 5 days. suggesting that control of peptide/siRNA molar ratio is essential to obtain stable and biologically efficient particles in culture medium, as already reported for other non-covalent peptide carriers [42, 44] . Indeed using fluorescent siRNA we have demonstrated that cellular uptake increases with the molar ratio but that at a ratio above 40/1, internalized levels of siRNA per cell were more heterogeneous.
CADY constitutes an interesting tool for ex-vivo siRNA delivery and can be applied to a large number of challenging cell lines. We have shown that CADY-mediated siRNA delivery is associated with a significant knockdown of the target gene at both mRNA and protein levels, in adherent, suspension and primary cell lines, with IC 50 values in the low nanomolar range. Furthermore, one of the advantages of CADY/siRNA particles is their high stability, which allows for serial dilution, whilst maintaining constant the peptide/siRNA molar ratio, and enables to achieve significant knockdown of the target at sub-nanomolar siRNA concentrations. In addition, CADY does not show any acute and long-term toxicity on transfected cells at any molar ratio applied, other than a slight effect on cell viability observed at a 10/1 ratio which might be attributable to particle size at this ratio. Indeed biophysical studies have revealed that particle size of CADY/siRNA complexes depends on their molar ratio and that at low ratios, particles tend to aggregate. Regarding these results and siRNA delivery experiments, complex stability and size are clearly critical parameters, which affect the cellular uptake mechanism, and consequently determine the outcome of the biological response.
The cellular uptake mechanism of CPPs is most often associated with the endosomal pathway and dependent on the cargo, cell line and local concentration of CPPs. We have investigated the mechanism through which CADY/siRNA enter cells and found that the use of inhibitors of the endosomal pathway barely affect cellular uptake and the associated hal-00345886, version 1 -5 Feb 2009 biological response. Moreover, we propose that the helical conformation of CADY is involved in the interactions with the cell membrane and in the process of cell penetration itself. JTS1, INF1 or KALA peptides have the tendency to adopt a helical structure at low pH, inducing the formation of an amphipathic helix with a strong potency to destabilize membranes and favour release from the endosome [34] . In contrast, CADY, like PPTG1, adopts a helical structure independently of the pH and cellular uptake was only slightly modified by inhibition of the vacuolar proton pump [35] , suggesting that the mechanism of these peptide is less sensitive to pH and only partially involves the endosomal pathway.
Although we cannot exclude another endosomal mechanism, it seems that CADY uptake is associated with its ability to interact with the cell membrane and that aromatic Trp residues play a major role by interacting with membrane components. Lack of toxicity associated with the helical conformation suggests a temporary interaction of CADY/siRNA complexes with the cell membrane, which is not the case for other helix-forming peptides that interact with membranes such as mellitin [45] . The helical conformation has a major impact on CPP cellular uptake and improves their release from endosomes, as reported for penetratin, transportan, proline-rich peptides and calcitonin-derived peptides [46] .
We have demonstrated that CADY/siRNA complexes enter cells rapidly and independently of the endosomal pathway. Similar data have been reported for other CPPs which exhibit a tendency to form complexes with membranes or at high concentrations [47] .
We suggest that particle organization upon interaction with the cell membrane,together with GAG clusterization may induced a local high concentration of CPP [47] , which, together with the Trp-residues present in the sequence, favour membrane penetration and rapid cellular entry. There is a critical balance between stability of the particle, CPP concentration and their ability to interact with the lipid phase of the membrane, as already reported for other CPPs. [48] ; In the case of MPG 4 mutations in the hydrophobic domain suffice to make the peptide more toxic and to promote cellular uptake through the endosomal pathway [49] .
In conclusion, CADY is the first secondary amphipathic peptide which allows the formation of stable complexes with siRNA via non covalent interactions and that efficiently promotes cellular uptake of suspension and challenging cell lines. Taking together these results, with the fact that CADY is not toxic and its ability to support a sustained silencing response with low nanomolar concentrations of siRNA, suggests that this peptide carrier is extremely efficient for silencing different target genes. Hence the peptide-based nanoparticle CADY-system constitutes a promising technology for siRNA delivery for therapeutic purposes. Its development for in vivo applications should reduce the dosage of therapeutic molecules, thereby limiting off-target effects and associated toxicity.
MATERIALS AND METHODS
Peptide synthesis and siRNA. CADY peptide (Ac-GLWRALWRLLRSLWRLLWRA-cya), was synthesized by solid-phase peptide synthesis synthesized using AEDI-expensin resin with (fluorenylmethoxy)-carbonyl (Fmoc) continuous (Pionner, Applied Biosystems, Foster city, CA) as described previously [31] . CADY was purified by semi-preparative reverse-phase Molecular modelling: 3D models of CADY were calculated using PepLook software [36] .
Briefly, a set of 99 3-D models were selected as the conformations of lower energy among the 10*CADY sequence, the CBMN semi-empirical Force Field and a set of backbone angles calibrated for optimal structure prediction [36] .
Intrinsic fluorescence spectroscopy. Fluorescence experiments were performed at 25°C, using a SPEX-PTI spectrofluorimeter in a 1 cm path-length quartz cuvette, with a band-pass of 2 nm for excitation and emission. The binding of siRNA to CADY was monitored by fluorescence microscopy in phosphate buffer. A fixed concentration of CADY (200 nM) was titrated by increasing siRNA concentrations from 1 to 500 nM. Intrinsic Trp-fluorescence was excited at 290 nm and emission spectra recorded from 310 to 400 nm. Data were fitted, using a quadratic equation (GraFit, Erithacus Software) as described previously [41] .
Serum nuclease protection assay.
Naked siRNA (50 fmol) or CADY/siRNA complexes formed as described above were incubated at 37°C in DMEM containing 50% FCS. After 24h, the reaction was stopped by adding Proteinase K (200 µg/ml) for 1 h at 37°C allowing also the digestion of CADY peptide. Then siRNA was extracted with phenol:chloroform and analyzed on a 1% agarose gel (w/v). Western blotting. Transfected cells were harvested by trypsination, washed in PBS and lysed in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 2 mM EDTA, 0.1% NP40, and 0.1% deoxycholate, including protease inhibitors: 10 µg/ml aprotinin, 10 µg/ml pepstatin A, 10 µg/ml leupeptin, and 1 mM PMSF (phenyl-methylsulfonyl fluoride). Cell lysates were kept on ice for 30 minutes, mixed every 5 min., and centrifuged at 4°C for 15 min. at 10,000g.
Supernatants were collected and protein concentrations were determined using the Bradford and the CADY associated siRNA protection to serum nucleases was evaluated on agarose gel after peptides and proteins digestion by Proteinase K and a phenol/chloroform extraction. Changes in GAPDH mRNA levels were normalized to non transfected cells 
